VivoSeq
Other

Mcrpc

0

Pipeline Programs↗

13

Active Trials↗

10

Companies Involved↗

mCRPC is an early-stage landscape with 0 programs across 10 companies. The most active players are Progenics Pharmaceuticals, Inc., Suzhou Kintor Pharmaceutical Inc,, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

65/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Progenics Pharmaceuticals, Inc.

0 programs

PreclinicalS

Suzhou Kintor Pharmaceutical Inc,

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalP

Pellficure Pharmaceuticals, Inc

0 programs

PreclinicalNovo Nordisk logo

Novo Nordisk

0 programs

PreclinicalT

Telix Pharmaceuticals (Innovations) Pty Limited

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

37

clinical trials

Completed13 · 35%
Recruiting8 · 22%
Terminated5 · 14%
Active, not recruiting4 · 11%
Unknown status3 · 8%
Withdrawn2 · 5%
Other2 · 5%

Clinical Trials

Trial Activity

37 trials

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06826768·60 enrolled
A Phase I Trial of A-CAR032 in Participants With mCRPC
Recruiting·SShanghai AbelZeta Ltd.·Phase 1·NCT07344311·27 enrolled
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
Recruiting·EErasmus Medical Center·Phase 2·NCT05762536·245 enrolled
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06136624·1,310 enrolled
Study With [225Ac]Ac-FL-020 in mCRPC Participants
Recruiting·FFull-Life Technologies GmbH·Phase 1·NCT06492122·50 enrolled
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Recruiting·TTelix Pharmaceuticals (Innovations) Pty Limited·Phase 3·NCT06520345·430 enrolled
TmPSMA-02 in mCRPC
Recruiting·UUniversity of Pennsylvania·Phase 1·NCT06046040·30 enrolled
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Recruiting·Novartis logoNovartis·Phase 3·NCT06855277·940 enrolled
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Active, not recruiting·EExelixis·Phase 3·NCT04446117·575 enrolled
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Active, not recruiting·—·Phase 1·NCT04846478·35 enrolled
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Active, not recruiting·OOncoC4, Inc.·Phase 1/2·NCT05682443·148 enrolled
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
Active, not recruiting·WWeill Medical College of Cornell University·Phase 1/2·NCT04506567·60 enrolled
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
Enrolling by invitation·BBritish Columbia Cancer Agency·Phase 1/2·NCT05570994·50 enrolled
The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC
Completed·SSuzhou Kintor Pharmaceutical Inc,·Phase 2·NCT03899467·61 enrolled
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
Completed·PProgenics Pharmaceuticals, Inc.·Phase 2·NCT03939689·120 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)